HHS awards $119M contract for antibiotic development, with a long 10-year performance period

Contract Overview

Contract Amount: $119,160,691 ($119.2M)

Contractor: Shionogi Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2026-04-06

End Date: 2036-03-10

Contract Duration: 3,626 days

Daily Burn Rate: $32.9K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.

Place of Performance

Location: FLORHAM PARK, MORRIS County, NEW JERSEY, 07932

State: New Jersey Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $119.2 million to SHIONOGI INC for work described as: LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS. Key points: 1. Contract focuses on critical need for new antibiotics against drug-resistant and biothreat pathogens. 2. Long performance period suggests a phased approach to development and potential for follow-on work. 3. Sole contractor, Shionogi Inc., indicates specialized expertise or a unique offering in this niche. 4. Cost-plus-fixed-fee structure incentivizes contractor to manage costs while pursuing development goals. 5. Contract value of $119M over 10 years implies significant investment in R&D for public health security. 6. Geographic focus on New Jersey for contract performance.

Value Assessment

Rating: good

The contract value of $119 million over a decade for antibiotic development appears reasonable given the high costs and long timelines associated with pharmaceutical R&D, especially for novel treatments against resistant pathogens. Benchmarking is difficult without specific details on the development stage and scope, but the investment aligns with public health priorities for biodefense and combating antimicrobial resistance. The cost-plus-fixed-fee structure allows for flexibility in research while providing a defined profit margin.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting that multiple capable vendors had the opportunity to bid. However, the award to a single contractor, Shionogi Inc., implies that they were selected as the most advantageous offer based on technical merit, proposed approach, and potentially price. The level of competition at the bid stage is not detailed, but the final award to one entity suggests a highly specialized field where few possess the required capabilities.

Taxpayer Impact: Full and open competition is generally favorable for taxpayers as it drives down prices through market forces. While this contract resulted in a single award, the initial competitive process likely ensured a fair price was established for the critical research and development services.

Public Impact

The primary beneficiaries are the public, through enhanced preparedness against drug-resistant infections and biothreats. Services delivered include late-stage development, FDA marketing authorization, and potential stockpile procurement of antibiotics. Geographic impact is primarily in New Jersey where the contractor is located, but the ultimate benefit is national public health security. Workforce implications include specialized jobs in biotechnology research, development, and regulatory affairs.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Long contract duration (10 years) could lead to cost overruns if development timelines are not met.
Reliance on a single contractor may pose risks if unforeseen issues arise with Shionogi Inc.'s capacity or performance.
The 'late-stage development' phase is critical and success is not guaranteed, despite significant investment.

Positive Signals

Addresses a critical public health need for novel antibiotics against serious threats.
Full and open competition at the outset suggests a robust selection process.
The extended performance period allows for sustained focus on complex R&D challenges.
Contractor has a clear objective: FDA marketing authorization and potential procurement.

Sector Analysis

This contract falls within the Biotechnology and Pharmaceutical sector, specifically focusing on Research and Development for infectious diseases and biodefense. The market for novel antibiotics is challenging due to high R&D costs, long development cycles, and limited market returns compared to other therapeutic areas. Government investment is crucial for stimulating development in areas with significant public health implications but less commercial incentive, such as combating antimicrobial resistance and preparing for biothreats. Comparable spending benchmarks are difficult to establish due to the specialized nature of biodefense R&D, but significant government funding is typical for such critical national security and public health initiatives.

Small Business Impact

The data indicates this contract was not set aside for small businesses (ss: false, sb: false). Given the specialized nature of late-stage pharmaceutical development and FDA authorization, it is unlikely that small businesses would typically be the primary awardees for such a large-scale, long-term contract. Subcontracting opportunities for small businesses may exist in supporting roles, but the core development and regulatory activities are likely to be handled by the prime contractor, Shionogi Inc.

Oversight & Accountability

Oversight for this contract will likely be managed by the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). Accountability measures will be tied to the Cost Plus Fixed Fee (CPFF) structure, requiring detailed reporting on expenditures and progress towards milestones. Transparency will be facilitated through contract reporting mechanisms, though specific details of the R&D process may be proprietary. Inspector General jurisdiction would apply to any allegations of fraud, waste, or abuse related to the contract funds.

Related Government Programs

Antimicrobial Resistance Initiatives
Biodefense and Countermeasures
Strategic National Stockpile
FDA Drug Approval Process
Pharmaceutical Research and Development Funding

Risk Flags

Long-term R&D success is not guaranteed.
Reliance on a single contractor.
Potential for cost escalation over the contract duration.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $119.2 million to SHIONOGI INC. LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.

Who is the contractor on this award?

The obligated recipient is SHIONOGI INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $119.2 million.

What is the period of performance?

Start: 2026-04-06. End: 2036-03-10.

What is the specific stage of antibiotic development targeted by this contract, and what are the key milestones for FDA authorization?

The contract specifies 'LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE'. This indicates that the antibiotics are expected to be beyond early discovery and preclinical testing, likely in Phase II or Phase III clinical trials, or potentially ready for submission of a New Drug Application (NDA) to the FDA. Key milestones for FDA authorization typically include successful completion of rigorous clinical trials demonstrating safety and efficacy, submission of a comprehensive NDA package containing all preclinical and clinical data, and successful review by the FDA, which may involve advisory committee meetings and facility inspections. The contract's long duration suggests it may encompass multiple antibiotics or complex development pathways requiring sustained effort over several years to achieve these critical regulatory approvals.

How does the $119 million contract value compare to typical investments in antibiotic R&D for biodefense purposes?

The $119 million contract value over a 10-year period represents a significant, albeit not unprecedented, investment in antibiotic R&D for biodefense. Developing a single new antibiotic can cost upwards of $1 billion, including R&D, clinical trials, and regulatory processes. However, government contracts often focus on specific stages or critical needs, such as late-stage development or addressing pathogens of national security concern, which may involve different funding structures and values than purely commercial ventures. This contract's value suggests a substantial commitment to advancing specific candidates or a platform technology aimed at combating drug-resistant infections and biothreat agents, aligning with public health security priorities where market incentives alone are often insufficient.

What are the primary risks associated with a 10-year performance period for a Cost Plus Fixed Fee (CPFF) contract in pharmaceutical R&D?

A 10-year performance period for a CPFF contract in pharmaceutical R&D presents several risks. Firstly, the extended timeline increases the potential for scope creep or evolving scientific understanding that may necessitate significant contract modifications, potentially impacting the fixed fee and overall cost. Secondly, CPFF contracts can incentivize contractors to incur costs, as their fee is a percentage of those costs, which, if not tightly managed, could lead to inefficiencies over such a long duration. For the government, the risk lies in the possibility that despite substantial investment, the R&D may not yield successful, approvable products within the projected timeframe or at all, given the inherent uncertainties in drug development. Robust oversight and clear milestone definitions are crucial to mitigate these risks.

Given the award to Shionogi Inc., what is their track record in developing antibiotics or addressing biothreat pathogens?

Shionogi Inc. has a notable track record in infectious disease research and development, including antibiotics. They have brought several antibiotics to market, addressing various bacterial infections. Their portfolio includes treatments for community-acquired bacterial pneumonia and other serious infections. While specific details on their work directly related to 'biothreat pathogens' as defined by government agencies might require deeper investigation into their pipeline and past government contracts, their established presence in the antibiotic space suggests relevant expertise. The government's decision to award this significant contract to Shionogi Inc. likely stems from their demonstrated capabilities in late-stage development, regulatory affairs, and potentially existing research relevant to the targeted pathogens.

How does the 'full and open competition' designation reconcile with a single award to Shionogi Inc.?

The 'full and open competition' designation means that the government advertised the requirement broadly and allowed all responsible sources to submit proposals. This initial phase is crucial for ensuring a competitive marketplace and identifying potential offerors. However, it does not guarantee multiple awards. In highly specialized fields like advanced pharmaceutical R&D for biodefense, it is common for only one or a few entities to possess the unique technical capabilities, intellectual property, infrastructure, and experience required to successfully execute the contract. Therefore, after a thorough evaluation process, Shionogi Inc. was likely determined to be the offeror providing the best value to the government, even if they were the sole awardee from the competitive pool.

What are the potential implications of this contract for the broader pharmaceutical market and antimicrobial resistance (AMR) efforts?

This contract has significant implications for both the pharmaceutical market and AMR efforts. By investing in late-stage development and FDA authorization for antibiotics targeting drug-resistant and biothreat pathogens, the government is directly addressing market failures in the antibiotic sector, where commercial returns often do not justify the high R&D costs. This public funding can de-risk development for companies like Shionogi Inc., encouraging innovation that might otherwise not occur. Furthermore, successful development and potential stockpiling contribute directly to national and global AMR preparedness, enhancing the availability of critical treatments and bolstering defenses against emerging infectious disease threats. It signals continued government commitment to tackling AMR through strategic procurement and R&D support.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 75A50125R00005

Offers Received: 1

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Parent Company: Shionogi & Company Limited

Address: 400 CAMPUS DR, FLORHAM PARK, NJ, 07932

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $481,678,318

Exercised Options: $119,160,691

Current Obligation: $119,160,691

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline